SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-017043
Filing Date
2022-05-02
Accepted
2022-05-02 16:06:25
Documents
51
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q abio-10q_20220331.htm   iXBRL 10-Q 1342400
2 EX-31.1 abio-ex311_8.htm EX-31.1 8575
3 EX-31.2 abio-ex312_6.htm EX-31.2 8578
4 EX-32.1 abio-ex321_7.htm EX-32.1 11226
5 GRAPHIC gw35eolrzjjg000001.jpg GRAPHIC 1063
  Complete submission text file 0001564590-22-017043.txt   3942138

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA abio-20220331.xsd EX-101.SCH 29087
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE abio-20220331_cal.xml EX-101.CAL 29188
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abio-20220331_def.xml EX-101.DEF 65805
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20220331_lab.xml EX-101.LAB 244388
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20220331_pre.xml EX-101.PRE 172782
45 EXTRACTED XBRL INSTANCE DOCUMENT abio-10q_20220331_htm.xml XML 459795
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 22881923
SIC: 2835 In Vitro & In Vivo Diagnostic Substances